UiPath (NYSE:PATH) Price Target Lowered to $17.00 at JPMorgan Chase & Co.

UiPath (NYSE:PATH) had its price objective reduced by stock analysts at JPMorgan Chase & Co. from $19.00 to $17.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 36.22% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company lowered their target price on shares of UiPath from $15.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday. BMO Capital Markets lifted their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a report on Friday, September 6th. Needham & Company LLC reissued a “hold” rating on shares of UiPath in a research note on Wednesday. Royal Bank of Canada restated a “sector perform” rating and issued a $16.00 price target on shares of UiPath in a research note on Friday, September 6th. Finally, Evercore ISI upped their price objective on UiPath from $13.00 to $16.00 and gave the stock an “in-line” rating in a report on Friday, September 6th. Sixteen analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $17.47.

UiPath Stock Up 3.5 %

PATH opened at $12.48 on Wednesday. The business has a 50 day moving average price of $12.48 and a two-hundred day moving average price of $14.23. UiPath has a 52 week low of $10.37 and a 52 week high of $27.87.

UiPath (NYSE:PATH) last released its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The business had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. During the same quarter in the prior year, the business earned ($0.09) earnings per share. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. As a group, equities analysts expect that UiPath will post -0.23 EPS for the current fiscal year.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.07, for a total transaction of $575,388.97. Following the completion of the transaction, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at $10,258,498.19. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.37% of the company’s stock.

Institutional Trading of UiPath

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PATH. Future Financial Wealth Managment LLC acquired a new stake in shares of UiPath during the 3rd quarter worth about $26,000. JTC Employer Solutions Trustee Ltd acquired a new stake in UiPath during the third quarter worth approximately $26,000. ORG Partners LLC grew its stake in UiPath by 875.6% in the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after acquiring an additional 1,112 shares during the period. Hantz Financial Services Inc. acquired a new position in UiPath in the 2nd quarter valued at $28,000. Finally, Redwood Wealth Management Group LLC purchased a new position in shares of UiPath during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.